Novel therapeutics in multiple myeloma

References

• Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114:5436–43.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al.. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–57.
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141:41–51.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al.. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27:5008–14.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, et al.. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934–9.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al.. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118:2970–5.
   PubMed Web of Science ®Google Scholar
• Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, et al.. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111:2765–75.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al.. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15:7085–91.
   PubMed Web of Science ®Google Scholar
• Richardson P, Hofmeister CC, Zimmerman TM, Chanan-Khan AA, Spear MA, Palladino MA, et al.. Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. ASH Annual Meeting Abstracts. 2008;112:2770.
   Google Scholar
• Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer. 2006;95:961–5.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Spencer A, Cannell P, Harrison SJ, Catley L, Underhill C, et al.. Phase 1 clinical evaluation of twice-weekly Marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts. 2011;118:302.
   Google Scholar
• Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, et al.. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011;17:7313–23.
   PubMed Web of Science ®Google Scholar
• Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 2011;7:607–12.
   PubMed Web of Science ®Google Scholar
• Wang L, Siegel DS, Jakubowiak AJ, Wong AF, Dixon S, Rebau TE, et al.. The speed of response to single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma: an exploratory analysis of results from 2 multicenter phase 2 clinical trials. ASH Annual Meeting Abstracts. 2011;118:3969.
   Google Scholar
• Singhal S, Siegel DS, Martin T, Vij R, Wang L, Jakubowiak AJ, et al.. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. ASH Annual Meeting Abstracts. 2011;118:1876.
   Google Scholar
• Vij R, Kaufman JL, Jakubowiak AJ, Wang M, Jagannath S, Kukreti V, et al.. Final results from the bortezomib-naive group of PX-171-004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. ASH Annual Meeting Abstracts. 2011;118:813.
   Google Scholar
• Jakubowiak AJ, Dytfeld D, Jagannath S, Vesole DH, Anderson TB, Nordgren BK, et al.. Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). ASH Annual Meeting Abstracts. 2011;118:631.
   Google Scholar
• Richardson PG, Mitsiades CS, Colson K, Reilly E, McBride L, Chiao J, et al.. Final results of a phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. ASH Annual Meeting Abstracts. 2007;110:1179.
   Google Scholar
• Weber D, Badros AZ, Jagannath S, Siegel D, Richon V, Rizvi S, et al.. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. ASH Annual Meeting Abstracts. 2008;112:871.
   Google Scholar
• Dimopoulos MA, Jagannath S, Yoon S-S, Siegel DS, Lonial S, Hajek R, et al.. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. ASH Annual Meeting Abstracts. 2011;118:811.
   Google Scholar
• Siegel D, Sezer O, San MJF, Mateos MV, Prosser I, Cavo M, et al.. A phase IB, multicenter, open-label, dose-escalation study of oral Panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. ASH Annual Meeting Abstracts. 2008;112:2781.
   Google Scholar
• Richardson PG, Alsina M, Weber DM, Coutre SE, Lonial S, Gasparetto C, et al.. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). ASH Annual Meeting Abstracts. 2011;118:814.
   Google Scholar
• San-Miguel JF, de Moraes Hungria VT, Yoon S-S, Wiktor-Jedrzejczak W, Elghandour A, Siritanaratkul N, et al.. Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. ASH Annual Meeting Abstracts. 2011;118:3976.
   Google Scholar
• Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–52.
   Web of Science ®Google Scholar
• Lonial S, Jakubowiak AJ, Jagannath S, Raab MS, Facon T, Vij R, et al.. A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts. 2011;118:303.
   Google Scholar
• Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, et al.. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105:2941–8.
   PubMed Web of Science ®Google Scholar
• Spencer A, Yoon S-S, Harrison SJ, Morris S, Smith D, Freedman SJ, et al.. Novel AKT inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Preliminary results from a phase I first-time-in-human study. ASH Annual Meeting Abstracts. 2011;118:1856.
   Google Scholar
• Tiedemann RE, Zhu YX, Schmidt J, Yin HW, Shi C-X, Que Q, et al.. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid restricted kinase, GRK6. Blood. 2010;115:1594–604.
   PubMed Web of Science ®Google Scholar